# Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders

> **NCT01624142** · PHASE2,PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 300 (actual)

## Conditions studied

- Severe Familial Hypercholesterolemia

## Interventions

- **BIOLOGICAL:** Evolocumab

## Key facts

- **NCT ID:** NCT01624142
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-01
- **Primary completion:** 2018-05-11
- **Final completion:** 2018-05-11
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2024-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01624142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01624142, "Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01624142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*